Nuvalent prices ~$165.75M IPO
- Biopharmaceutical company Nuvalent (NUVL) has priced its initial public offering of 9,750,000 common shares, with expected gross proceeds of ~$165.75M.
- The offering consists of 9,150,000 shares of Class A common stock and 600,000 shares of Class B common…
